Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus

Randomized Controlled Trial

. 2014 Jan-Feb;8(1):61-8.

doi: 10.1016/j.jacl.2013.11.003. Epub 2013 Nov 11.

Affiliations

PMID: 24528686
DOI: 10.1016/j.jacl.2013.11.003

Randomized Controlled Trial

Massimiliano Ruscica et al. J Clin Lipidol. 2014 Jan-Feb.

Abstract

Background: Primary cardiovascular prevention may be achieved by lifestyle/nutrition improvements and specific drugs, although a relevant role is now emerging for specific functional foods and nutraceuticals.

Objectives: The aim of this study was to evaluate the usefulness of a nutraceutical multitarget approach in subjects with moderate cardiovascular risk and to compare it with pravastatin treatment.

Subjects: Thirty patients with moderate dyslipidemia and metabolic syndrome (according to the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults) were included in an 8-week randomized, double-blind crossover study and took either placebo or a nutraceutical combination that contained red yeast rice extract, berberine, policosanol, astaxanthin, coenzyme Q10, and folic acid (Armolipid Plus). Subsequently, they were subjected to another 8-week treatment with pravastatin 10 mg/d. This dosage was selected on the basis of its expected -20% efficacy in reducing low-density lipoprotein-cholesterol.

Results: Treatment with Armolipid Plus led to a significant reduction of total cholesterol (-12.8%) and low-density lipoprotein-cholesterol (-21.1%), similar to pravastatin (-16% and -22.6%, respectively), and an increase of high-density lipoprotein-cholesterol (4.8%). Armolipid Plus improved the leptin-to-adiponectin ratio, whereas adiponectin levels were unchanged.

Conclusions: These results indicate that this nutraceutical approach shows a lipid-lowering activity comparable to pravastatin treatment. Hence, it may be a safe and useful option, especially in conditions of moderate cardiovascular risk, in which a pharmacologic intervention may not be appropriate.

Keywords: Berberine; Cardiovascular risk; HDL-cholesterol; LDL-cholesterol; Monacolin K.

PubMed Disclaimer

Cited by

A systematic, updated review of Xuezhikang, a domestically developed lipid-lowering drug, in the application of cardiovascular diseases.
Yang C, Wu Y, Qian J, Li JJ. Yang C, et al. Acta Pharm Sin B. 2024 Oct;14(10):4228-4242. doi: 10.1016/j.apsb.2024.05.011. Epub 2024 May 11. Acta Pharm Sin B. 2024. PMID: 39525586 Free PMC article. Review.
Astaxanthin Alleviates Hepatic Lipid Metabolic Dysregulation Induced by Microcystin-LR.
Tan Q, Chu H, Wei J, Yan S, Sun X, Wang J, Zhu L, Yang F. Tan Q, et al. Toxins (Basel). 2024 Sep 18;16(9):401. doi: 10.3390/toxins16090401. Toxins (Basel). 2024. PMID: 39330859 Free PMC article.
The Lipid-Lowering Efficacy of a Nutraceutical Combination Including Leucoselect Phytosome, Red Yeast Rice, Policosanol and Folic Acid in Dyslipidaemia Patients: Real-World Insights.
Russo V, Napolitano N, Ascrizzi A, Leonardi S, Pisacane F, Di Micco P, Imbalzano E, Sasso FC, D'Andrea A, Caturano A, Mauriello A. Russo V, et al. Pharmaceuticals (Basel). 2024 Mar 30;17(4):447. doi: 10.3390/ph17040447. Pharmaceuticals (Basel). 2024. PMID: 38675408 Free PMC article.
Pravastatin for lowering lipids.
Adams SP, Alaeiilkhchi N, Tasnim S, Wright JM. Adams SP, et al. Cochrane Database Syst Rev. 2023 Sep 18;9(9):CD013673. doi: 10.1002/14651858.CD013673.pub2. Cochrane Database Syst Rev. 2023. PMID: 37721222 Free PMC article. Review.
Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review.
Cicero AFG, Fogacci F, Stoian AP, Toth PP. Cicero AFG, et al. Nutrients. 2023 May 12;15(10):2288. doi: 10.3390/nu15102288. Nutrients. 2023. PMID: 37242171 Free PMC article. Review.

Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus - PubMed (original) (raw)